Q2 Earnings Forecast for Korro Bio Issued By Lifesci Capital

Korro Bio, Inc. (NASDAQ:KRRO) – Lifesci Capital issued their Q2 2026 earnings estimates for shares of Korro Bio in a report issued on Friday, May 29th. Lifesci Capital analyst T. Pardo-Garcia forecasts that the company will earn ($2.10) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($5.38) per share. Lifesci Capital also issued estimates for Korro Bio’s Q3 2026 earnings at ($1.81) EPS, Q4 2026 earnings at ($1.56) EPS, FY2026 earnings at ($5.15) EPS, FY2027 earnings at ($4.93) EPS, FY2028 earnings at ($4.87) EPS, FY2029 earnings at ($5.27) EPS and FY2030 earnings at ($4.57) EPS.

KRRO has been the subject of several other research reports. HC Wainwright lowered their target price on shares of Korro Bio from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Cantor Fitzgerald upped their target price on shares of Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Friday, March 13th. William Blair upgraded shares of Korro Bio from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Citigroup began coverage on shares of Korro Bio in a report on Monday, May 18th. They issued a “buy” rating and a $21.00 target price for the company. Finally, Wall Street Zen upgraded shares of Korro Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Korro Bio has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

Korro Bio Trading Down 3.6%

Shares of NASDAQ:KRRO opened at $12.93 on Tuesday. The company’s 50 day moving average is $12.37 and its two-hundred day moving average is $10.63. Korro Bio has a 52 week low of $5.20 and a 52 week high of $55.89. The company has a market cap of $186.49 million, a PE ratio of -1.11 and a beta of 3.07.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 117.86%.

Insider Buying and Selling

In other news, major shareholder Edward T. Mathers bought 207,100 shares of Korro Bio stock in a transaction dated Tuesday, March 10th. The stock was bought at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the purchase, the insider owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. The trade was a 18.99% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Mohamad Makhzoumi bought 207,100 shares of Korro Bio stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the purchase, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 1,657,320 shares of company stock worth $18,412,560. 4.80% of the stock is currently owned by insiders.

Institutional Trading of Korro Bio

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in shares of Korro Bio in the 3rd quarter worth $39,000. PNC Financial Services Group Inc. purchased a new position in shares of Korro Bio in the 3rd quarter valued at about $140,000. Wealth Forward LLC purchased a new position in shares of Korro Bio in the 3rd quarter valued at about $240,000. Algert Global LLC purchased a new position in shares of Korro Bio in the 3rd quarter valued at about $340,000. Finally, Wells Fargo & Company MN increased its holdings in shares of Korro Bio by 45.5% in the 4th quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after purchasing an additional 2,352 shares in the last quarter. Institutional investors and hedge funds own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.